Menu Search
Equities

Telo Genomics Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3D0A:STU

Telo Genomics Corp

Actions
  • Price (EUR)0.0245
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-66.21%
  • Beta0.0425
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Telo Genomics Corp. is a molecular diagnostics company that is engaged in developing the telomere analysis platform Teloview to enable the development of diagnostic and prognostic applications based on the quantification of genomic instability as a disease predictor. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. It quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-2.71m
  • Incorporated2011
  • Employees8.00
  • Location
    Telo Genomics CorpMars Centre, 101 College St Suite 200TORONTO M5G 1L7CanadaCAN
  • Phone+1 (416) 673-8487
  • Fax+1 (204) 582-0922
  • Websitehttps://www.telodx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.